In a previous retrospective survey, the investigators have shown that biomarkers and echomarkers could better stratify AF patients at increased cardiovascular risk. However, due to its retrospective design and the lack of completeness, the investigators could not validate a new risk score including all these markers and taking into account both thromboembolic and hemorrhagic risk. Indeed, these usual biologic and morphologic parameters will be obtained at admission in all patients in a prospective design.